FDA Approves Aprocitentan (Tryvio) for Hypertension: A Significant Breakthrough

In March 2024, the Food and Drug Administration (FDA) approved aprocitentan, branded as Tryvio, an innovative endothelin receptor antagonist. This new medication is intended for patients with hypertension who have not achieved adequate blood pressure control with existing antihypertensive treatments.

Understanding the Breakthrough

Tryvio is the first FDA-approved endothelin receptor antagonist for treating hypertension. Endothelin is a powerful vasoconstrictor that plays a crucial role in maintaining blood pressure. By blocking endothelin receptors, aprocitentan helps relax blood vessels and reduce blood pressure.

Efficacy: Meeting the Mark

The approval was based on the PRECISION study, a multipart, phase 3 multicenter trial conducted by Idorsia Pharmaceuticals. This comprehensive study included three phases: a 4-week placebo run-in, a 4-week double-blind randomized period comparing 12.5 mg and 25 mg of aprocitentan to placebo, a 32-week single-blind period with all patients receiving 25 mg of aprocitentan, and a 12-week double-blind withdrawal phase.

Results from the initial 4-week period showed that aprocitentan significantly reduced sitting systolic blood pressure (SiSBP) by 3.8 mmHg more than placebo, with similar reductions in diastolic blood pressure. These findings were consistent across different patient subgroups.

The sustained efficacy of aprocitentan was demonstrated in the withdrawal phase. Patients who were reassigned to placebo saw their blood pressure increase, whereas those who continued on aprocitentan maintained their blood pressure improvements.

Safety Profile

Like all medications, aprocitentan comes with its own set of side effects. Approximately 30% of patients in the PRECISION study reported edema or fluid retention, mostly mild to moderate. Serious cases of fluid retention occurred in less than 1% of patients.

Similarly, 0.8% of patients experienced hypersensitivity reactions, such as rash or allergic reactions, during the initial 4-week double-blind period. Common side effects (occurring in at least 2% of patients) included headache, dizziness, nasal congestion, and fatigue.

Discontinuation due to adverse events was relatively rare, with only a small number of patients stopping the medication. Importantly, aprocitentan is contraindicated in patients with severe kidney failure (estimated glomerular filtration rate [eGFR] below 30 mL/min/1.73 m2).

Dosing and Administration

Tryvio is available in two tablet strengths: 12.5 mg and 25 mg, both taken orally once daily. The 12.5-mg dose is recommended for most patients. The medication can be taken with or without food, but it is important to maintain consistency in dosage timing.

It’s crucial to adhere to the prescribed dose as higher doses are not approved and can increase the risk of side effects. Any changes in medication dosing or discontinuation should be supervised by a healthcare provider.

Conclusion

The FDA’s approval of aprocitentan (Tryvio) represents a significant advancement in hypertension management. Its efficacy in reducing blood pressure, combined with its manageable safety profile, offers a new option for patients who have not achieved adequate control with existing medications.

For healthcare providers and patients alike, understanding the medication’s benefits and potential side effects is crucial for effective treatment planning.

To stay informed about the latest developments in medical treatments and research, follow our updates regularly.

To read more about this and other important medical developments, download the January/February issue of Drug Topics here.

Your thoughts and experiences with this news are valuable. We encourage you to share your insights below!

Feel free to comment, subscribe to our newsletter, or share this article on your social media to help spread the word.